Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
Compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's
Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast